Endometrial hyperplasia is caused by too much estrogen stimulating the uterine lining without enough progesterone to keep that growth in check. This hormonal imbalance, called “unopposed estrogen,” is the driving force behind virtually every case. The specific conditions that create this imbalance range from common ones like obesity and irregular ovulation to less frequent causes like hormone-secreting ovarian tumors.
How Unopposed Estrogen Drives Overgrowth
During a normal menstrual cycle, estrogen thickens the uterine lining in the first half, building it up in preparation for a potential pregnancy. Then, after ovulation, progesterone takes over. It stops that estrogen-driven growth and shifts the lining into a mature, stable state. If no pregnancy occurs, progesterone levels drop, and the lining sheds as a period. The cycle resets.
When progesterone is missing or insufficient, estrogen keeps stimulating the lining with no braking mechanism. Estrogen triggers cell growth through several pathways, including signaling that activates growth factors in the tissue surrounding the uterine lining cells. These growth factors then push the lining cells to multiply. Normally, progesterone blocks this chain reaction. Without it, the lining continues to thicken, the cells crowd together, and the tissue can begin to look abnormal under a microscope. Over time, if the imbalance persists, some of these cells can accumulate genetic mutations that move them closer to cancer.
Obesity: The Most Common Risk Factor
Fat tissue is not just a passive energy store. It functions as an active hormone-producing organ. Adipose tissue contains an enzyme called aromatase that converts androgens (hormones produced by the adrenal glands) into estrogen. The more fat tissue you carry, the more estrogen your body produces through this route.
This matters because the estrogen generated by fat tissue acts on the uterine lining continuously, without the cyclical progesterone opposition that comes from regular ovulation. Obesity also creates chronic low-grade inflammation through disrupted signaling molecules released by fat cells, which adds a second layer of risk. The combination of persistent estrogen exposure and an inflammatory environment makes the endometrium especially vulnerable to abnormal growth. This is why obesity is one of the strongest and most consistent risk factors for both endometrial hyperplasia and endometrial cancer.
Polycystic Ovary Syndrome and Chronic Anovulation
PCOS is one of the most common hormonal disorders in women of reproductive age, and it creates a near-perfect setup for endometrial hyperplasia. Women with PCOS frequently have irregular or absent ovulation. Without ovulation, no corpus luteum forms in the ovary, and without a corpus luteum, progesterone levels stay low. Meanwhile, the ovaries continue producing estrogen, so the uterine lining keeps thickening cycle after cycle without ever fully shedding.
The risk is compounded by several features of PCOS. Many women with the condition also have higher insulin levels, which increases free estrogen and testosterone in the blood. And because PCOS is closely linked with higher body weight, the adipose tissue pathway adds even more estrogen to the mix. Research shows that women with both PCOS and endometrial hyperplasia have a fourfold greater risk of developing endometrial cancer compared to women without PCOS. The result is often unpredictable bleeding patterns, prolonged periods, or heavy menstrual bleeding, all of which can be early signs of a thickened lining.
The Perimenopause Window
The years leading up to menopause are a surprisingly high-risk period for endometrial hyperplasia. During perimenopause, hormone levels become erratic. Ovulation becomes intermittent and eventually stops, but the ovaries continue producing estrogen for months or even years. This creates the same unopposed estrogen scenario seen in PCOS, just through a different mechanism. Without regular ovulation, progesterone levels drop, and the endometrium is exposed to estrogen stimulation without the usual monthly reset.
The resulting bleeding tends to be irregular, prolonged, and heavy. Because the lining thickens unevenly and outgrows its blood supply, it sheds in patches rather than all at once. Many women assume this is simply “normal menopause stuff,” but persistent irregular bleeding during perimenopause warrants evaluation, as it can signal hyperplasia developing underneath.
Medications That Act Like Estrogen
Tamoxifen, widely used in breast cancer treatment, is the most well-known medication linked to endometrial hyperplasia. It works by blocking estrogen in breast tissue, but it has the opposite effect in the uterus, where it actually mimics estrogen and stimulates the lining. This dual personality makes it a selective estrogen receptor modulator: anti-estrogen in the breast, pro-estrogen in the uterus.
The incidence of endometrial hyperplasia in postmenopausal women taking tamoxifen ranges from about 1.3% to 20%, compared to 0 to 10% in postmenopausal breast cancer patients not on the drug. Tamoxifen can cause a range of uterine changes, from polyps and hyperplasia to, in rare cases, endometrial cancer. Women on tamoxifen are typically monitored for abnormal bleeding for this reason.
Estrogen-only hormone replacement therapy (without progesterone) carries a similar risk. This is why modern HRT for women who still have a uterus almost always includes a progestin component to protect the lining.
Estrogen-Producing Ovarian Tumors
A less common but important cause is ovarian tumors that secrete estrogen directly. Granulosa cell tumors are the most frequent type, accounting for 2 to 5% of ovarian cancers. These tumors produce estradiol continuously, flooding the endometrium with estrogen. The prolonged exposure creates a wide spectrum of endometrial problems, from simple hyperplasia to cancer.
Because these tumors can grow slowly and produce symptoms that overlap with normal hormonal fluctuations (irregular bleeding, pelvic fullness), they’re sometimes discovered only when a biopsy reveals unexplained hyperplasia and the workup traces the cause back to the ovary.
How Hyperplasia Is Classified
Not all endometrial hyperplasia carries the same level of concern. The current classification system divides it into two categories based on whether the cells look abnormal under a microscope.
Hyperplasia without atypia means the lining is thickened and overgrown, but the cells themselves still look normal. This is a benign condition. It typically regresses once the hormonal imbalance is corrected, whether through restoring regular ovulation, progesterone treatment, or a hormonal IUD. The risk of this type progressing to cancer is less than 5% over 20 years.
Atypical hyperplasia is a different situation entirely. Here, the cells have begun to look abnormal, and genetic testing reveals many of the same mutations found in early endometrial cancer. Up to 60% of women with atypical hyperplasia either already have coexisting cancer that hasn’t been detected yet or will develop invasive cancer if the condition is left untreated. The 20-year cumulative progression risk is roughly 28%. This type is treated much more aggressively, often with surgery.
Recognizing the Symptoms
The hallmark symptom is abnormal uterine bleeding. What that looks like depends on your age and stage of life. In premenopausal women, it typically shows up as heavy periods (soaking through pads or tampons quickly, passing clots), bleeding between periods, or cycles that are significantly shorter or longer than usual. In postmenopausal women, any vaginal bleeding is considered abnormal and should prompt evaluation.
Some women with hyperplasia also develop anemia from chronic blood loss, which can cause fatigue, pallor, and shortness of breath with exertion. In some cases, the condition is discovered incidentally when an ultrasound performed for another reason reveals a thickened endometrial lining. For postmenopausal women without symptoms, a lining thicker than 11 mm on ultrasound, especially with irregular texture or increased blood flow, generally warrants further investigation such as a biopsy.
Who Is Most at Risk
The common thread linking nearly all risk factors is prolonged estrogen exposure without progesterone balance. In practical terms, that means higher risk for women who:
- Are significantly overweight or obese, due to estrogen production in fat tissue
- Have PCOS or other causes of chronic anovulation, which eliminates the progesterone phase of the cycle
- Are in perimenopause, when ovulation becomes irregular
- Take estrogen-only hormone therapy without a progestin
- Use tamoxifen for breast cancer treatment or prevention
- Started menstruating early or reached menopause late, both of which extend lifetime estrogen exposure
- Have never been pregnant, since pregnancy provides prolonged progesterone exposure
Many of these factors overlap. A woman with PCOS who also carries excess weight and has irregular cycles faces compounding sources of unopposed estrogen, each reinforcing the others. Understanding the specific cause matters because treatment is most effective when it targets the underlying hormonal imbalance rather than just the thickened lining itself.